NSE - Delayed Quote • INR
Glenmark Pharmaceuticals Limited (GLENMARK.NS)
At close: 3:30 PM GMT+5:30
Breakdown
TTM
3/31/2023
3/31/2022
3/31/2021
Total Revenue
128,713,100.00
127,254,330.00
121,741,980.00
108,060,260.00
Cost of Revenue
51,992,130.00
48,832,800.00
47,781,710.00
39,966,250.00
Gross Profit
76,720,970.00
78,421,530.00
73,960,270.00
68,094,010.00
Operating Expense
65,459,680.00
61,735,090.00
55,559,790.00
50,933,650.00
Operating Income
11,261,290.00
16,686,440.00
18,400,480.00
17,160,360.00
Net Non Operating Interest Income Expense
-4,543,280.00
-3,268,170.00
-2,886,640.00
-3,504,660.00
Pretax Income
-5,541,190.00
8,684,510.00
14,412,460.00
13,824,750.00
Tax Provision
1,206,150.00
4,910,510.00
4,475,970.00
4,123,870.00
Net Income Common Stockholders
-7,116,880.00
2,972,450.00
9,417,110.00
9,700,380.00
Diluted NI Available to Com Stockholders
-7,116,880.00
2,972,450.00
9,417,110.00
9,700,380.00
Basic EPS
-25.22
10.53
33.37
34.38
Diluted EPS
-25.22
10.53
33.37
34.38
Basic Average Shares
282,207.74
282,168.16
282,168.16
282,168.16
Diluted Average Shares
282,207.74
282,168.16
282,168.16
282,168.16
Rent Expense Supplemental
--
560,240.00
353,540.00
378,990.00
Total Expenses
117,451,810.00
110,567,890.00
103,341,500.00
90,899,900.00
Net Income from Continuing & Discontinued Operation
-7,116,880.00
2,972,450.00
9,417,110.00
9,700,380.00
Normalized Income
1,107,673.00
8,304,147.00
11,260,507.23
9,385,322.00
Interest Income
--
227,660.00
94,350.00
26,470.00
Interest Expense
4,770,940.00
3,495,830.00
2,980,990.00
3,531,130.00
Net Interest Income
-4,543,280.00
-3,268,170.00
-2,886,640.00
-3,504,660.00
EBIT
-770,250.00
12,180,340.00
17,393,450.00
17,355,880.00
EBITDA
5,306,530.00
18,293,020.00
22,260,600.00
21,791,420.00
Reconciled Cost of Revenue
51,992,130.00
48,832,800.00
47,781,710.00
39,966,250.00
Reconciled Depreciation
6,076,780.00
6,112,680.00
4,867,150.00
4,435,540.00
Net Income from Continuing Operation Net Minority Interest
-7,640,360.00
2,972,450.00
9,417,110.00
9,700,380.00
Total Unusual Items Excluding Goodwill
-12,497,190.00
-7,616,710.00
-2,673,770.00
448,990.00
Total Unusual Items
-12,497,190.00
-7,616,710.00
-2,673,770.00
448,990.00
Normalized EBITDA
17,803,720.00
25,909,730.00
24,934,370.00
21,342,430.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,749,157.00
-2,285,013.00
-830,372.77
133,932.00
3/31/2021 - 7/1/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GRANULES.NS Granules India Limited
424.05
+1.46%
AUROPHARMA.NS Aurobindo Pharma Limited
1,131.30
+2.53%
APLLTD.NS Alembic Pharmaceuticals Limited
990.25
-0.73%
AJANTPHARM.NS Ajanta Pharma Limited
2,193.50
+2.50%
ZYDUSLIFE.NS Zydus Lifesciences Limited
947.40
-0.40%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
2,691.00
-0.12%
GLS.NS Glenmark Life Sciences Limited
814.95
+8.59%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,506.55
-0.89%
DIVISLAB.NS Divi's Laboratories Limited
4,016.35
+4.49%
LUPIN.NS Lupin Limited
1,615.95
+1.35%